a balanced article which also points out discontinuations and variable benefits. Not sure I'm more confident having read this although given no other treatment is available a case by case use would seem reasonable given safety is fine. This would then mean fda might lean towards approval. - I hope for all concerned.
a balanced article which also points out discontinuations and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.17 |
Change
-0.400(2.75%) |
Mkt cap ! $1.773B | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.56 | $14.16 | $1.098M | 76.87K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7 | $14.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.18 | 636 | 10 |
View Market Depth
| Last trade - 11.19am 14/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |